melphalan 2mg tablets
a a h pharmaceuticals ltd - melphalan - oral tablet - 2mg
melphalan 2mg tablets
alliance healthcare (distribution) ltd - melphalan - oral tablet - 2mg
melphalan 50mg powder and solvent for solution for injection vials
tillomed laboratories ltd - melphalan hydrochloride - powder and solvent for solution for injection - 50mg
melphalan 50mg powder and solvent for solution for injection vials
sun pharma uk ltd - melphalan hydrochloride - powder and solvent for solution for injection - 50mg
evomela- melphalan injection, powder, lyophilized, for solution
acrotech biopharma inc - melphalan hydrochloride (unii: 1vxp4v453t) (melphalan - unii:q41or9510p) - evomela is indicated for use as a high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma. history of serious allergic reaction to melphalan. risk summary based on its mechanism of action, evomela can cause fetal harm when administered to a pregnant woman, including teratogenicity and/or embryo-fetal lethality [see clinical pharmacology (12.1)] . melphalan is a genotoxic drug and can cause chromatid or chromosome damage in humans [see nonclinical toxicology (13.1)] . in animal studies, melphalan was embryolethal and teratogenic in rats at doses below the recommended clinical doses [see data] . advise a pregnant woman of the potential risk to a fetus.. the background risk of major birth defects and miscarriage for the indicated populations are unknown. however, the background risk in the u.s. general population of major birth defects is 2-4% and of miscarriage is 15-20% of clinically recognized pregnancies. data animal data adequate ani
evomela- melphalan injection, powder, lyophilized, for solution
cenexi - bla - melphalan hydrochloride (unii: 1vxp4v453t) (melphalan - unii:q41or9510p) - evomela is indicated for use as a high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma. history of serious allergic reaction to melphalan. risk summary based on its mechanism of action, evomela can cause fetal harm when administered to a pregnant woman, including teratogenicity and/or embryo-fetal lethality [see clinical pharmacology ( 12.1)] . melphalan is a genotoxic drug and can cause chromatid or chromosome damage in humans [see nonclinical toxicology ( 13.1)] . in animal studies, melphalan was embryolethal and teratogenic in rats at doses below the recommended clinical doses [see data] . advise a pregnant woman of the potential risk to a fetus.. the background risk of major birth defects and miscarriage for the indicated populations are unknown. however, the background risk in the u.s. general population of major birth def
melphalan tillomed 50 mg inj./inf. sol. (pwdr. + solv.) i.arter./i.v. vial
tillomed pharma gmbh - melperone hydrochloride 55,973 mg - eq. melphalan 50 mg - powder and solvent for solution for injection/infusion - 50 mg - melperone hydrochloride 55.973 mg - melphalan
alkeran
pharmacy retailing (nz) ltd t/a healthcare logistics - melphalan 50mg - solution for injection - 50 mg - active: melphalan 50mg excipient: hydrochloric acid povidone ethanol propylene glycol sodium citrate dihydrate
alkeran 50mg, powder and solvent for solution for infusion
aspen pharma trading limited - melphalan - powder and solvent for solution for infusion - 50 milligram(s) - nitrogen mustard analogues; melphalan
alkeran 2 mg film-coated tablets
aspen pharma trading limited - melphalan - film-coated tablet - 2 milligram(s) - nitrogen mustard analogues; melphalan